Latest Trastuzumab Stories
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status.
Two new studies presented at the ESMO 2012 Congress in Vienna, Austria show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy, but raise concerns about whether enough women are being offered these approaches.
The Vall d'Hebron Breast Cancer Unit, the Vall d'Hebron Institute of Oncology (VHIO) and SOLTI, an academic breast cancer research group are heading up a multi-center international study involving four Spanish and three North American research centers.
A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors.
Women who have breast cancer and are treated with two chemotherapy drugs may experience more cardiac problems like heart failure than shown in previous studies.
A team of researchers at Case Western Reserve University School of Medicine, led by Dr. Mark W. Jackson, have developed a novel method to identify genes that, when overexpressed, make normal cells behave like cancer cells.
A study conducted at Boston University School of Medicine (BUSM) demonstrates an effective combination therapy for breast cancer cells in vitro.
- A transitional zone between two communities containing the characteristic species of each.